FreeTheAI

Tempus AI Clinical Study Shows AI Tool Identifies Biomarkers in Lung Cancer Cases

MixedMedium impact
TEM$64.72 −9.01%

Tempus AI, Inc. (NASDAQ:TEM) presented study results showing its artificial intelligence pre-screening panel accurately identified potential biomarkers in patients with advanced non-small cell lung cancer. In a multi-center study analyzing 60,459 cases across 56,969 patients, the tool achieved greater than 80% sensitivity across all 12 biomarkers assessed, with sensitivity exceeding 90% for several markers. Results were shared at the European Society for Medical Oncology Congress in Madrid.

The study was conducted through an ongoing collaboration with Pfizer aimed at removing diagnostic barriers in cancer treatment. Identifying appropriate biomarkers currently requires tissue-intensive testing that can delay therapy. By analyzing routine pathology slide images already generated during care, the pre-screening tool is designed to help clinicians prioritize follow-up tests and accelerate decision-making while conserving tissue.

The technology remains under development and is not intended to replace formal molecular testing. Investors continue to evaluate the clinical progress and commercial potential of the company's diagnostic product pipeline. Shares of the company were down 9.01% at $64.72 following the announcement.

Key points

  • Tempus AI study demonstrated over 80% sensitivity across 12 lung cancer biomarkers using AI pre-screening.
  • The multi-center study evaluated 60,459 cases across 56,969 patients with advanced non-small cell lung cancer.
  • The research was conducted through an ongoing diagnostic collaboration between Tempus AI and Pfizer.
  • The AI tool analyzes routine pathology slide images to help prioritize follow-up molecular testing.

Written by our AI from expert market sources across the web. It can contain mistakes: check the facts before acting on them. Write-ups powered by the free AI API at FreeTheAI.org

How we writeDisclaimer

Questions and answers

What were the main results of the Tempus AI lung cancer study?

The AI pre-screening panel achieved over 80% sensitivity across 12 biomarkers, with sensitivity exceeding 90% for several markers in advanced lung cancer cases.

Will the new Tempus AI tool replace standard laboratory testing?

No, the tool remains under development and is designed to help prioritize and guide diagnostic testing rather than replace formal molecular tests.

Who collaborated with Tempus AI on this research?

The study was conducted through an ongoing collaboration between Tempus AI and Pfizer to address testing barriers in cancer care.